Ann: Bisantrene with Decitabine Enhances Cancer Cell Killing, page-58

Just want to really highlight this point. I think it's in everyone's best interest if Astex/Otsuka were to expedite a P1 basket Inqovi+Zan trial (very similar to the Dox+Zan we're waiting to hear more on).

RAC have just provided cause for Astex to pursue Inqovi in 13 new indications. I can't see Astex sitting on their hands for a couple of years for interim results for a synergy in an indication they're already servicing.



Astex' patent clock is already winding down. Why would they sit on the sidelines for a drug synergy that could 10 x their TAM... considering there's already 34 clinical trials currently recruiting for Inqovi synergy opportunities?